Alde­vron and In­scrip­ta ink man­u­fac­tur­ing deal for CRISPR Type-V nu­cle­ase

A plan to broad­en ac­cess to CRISPR has at­tract­ed a chunk of fund­ing and is now see­ing its wings spread.

Far­go-based DNA and mR­NA pro­duc­er Alde­vron has signed an agree­ment with life sci­ences com­pa­ny In­scrip­ta to man­u­fac­ture and com­mer­cial­ize the Eu­re­ca-V Nu­cle­ase, a wild-type MAD7 CRISPR Type-V nu­cle­ase.

This part­ner­ship will aim to of­fer this nu­cle­ase as a stan­dard re­search-grade and GMP cat­a­log item. Ac­cord­ing to a press re­lease, the pro­duc­tion of Eu­re­ca-V is slat­ed to start in Q3 of 2022. Fi­nan­cial de­tails of the deal were not im­me­di­ate­ly made avail­able to End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER